Klinikleitung

• Stammzelltransplantation
• Immunzelltherapien
• Chimärische Antigenrezeptor T Zellen
• Apheresen
• Sprechstunde, Beratung und Zweitmeinung nach Vereinbarung

• Experimentelle Stammzelltransplantation
• Graft-vs-Host Erkrankung
• Immunrekonstitution nach Transplantation

Original Papers

• Bankova AK, Pasin C, Huang A, Cicin-Sain C, Epp S, Audige A, Mueller NJ, Nilsson J, Vilinovszki O, Nair G, Wolfensberger N, Hockl P, Schanz U, Trkola A, Kouyos R, Hasse B, Zinkernagel AS, Manz MG, Abela IA, Müller AMS Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. Br J Haematol. 2022 Nov 16. doi: 10.1111/bjh.18562
• Ruder J, Docampo MJ, Rex J, Obahor S, Naghavian R, Müller AMS, Schanz U, Jelcic I, Martin R. Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis. Sci Transl Med. 2022 Nov 2;14(669):eabq1693. doi: 10.1126/scitranslmed.abq1693
• Ruder JF, Dinner G, Maceski AM, Correa EB, Müller AM, Jelcic I, Kuhle J, Martin R. Dynamics of inflammatory and neurodegenerative bi-omarkers after autologous hematopoietic stem cell transplantation in multiple sclerosis. Int J Mol Sci. 2022 Sep 19;23(18):10946. doi: 10.3390/ijms231810946
• Ring A, Grob B, Aerts E, Ritter K, Volbracht J, Schär B, Greiling M, Müller AMS. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. Annals of Hematology, published online June 27^th 2022, doi.org/10.1007/s00277-022-04881-0
• Sebastian Stolz, Marco Roncador, Wiebke Rösler, Thorsten Zenz, Markus G. Manz, Antonia M.S. Müller*, Corinne C. Widmer. Introducing innovative cellular therapies into the clinic: a 2-year retrospective analysis of chimeric antigen receptor T-cell experience at a single center in Switzerland; accepted for publication SMW
• Huang A, Cicin-Sain C, Pasin C, Epp S, Audigé A, Müller NJ, Nilsson J, Bankova A, Wolfensberger N, Vilinovszki O, Nair G, Hockl P, Schanz U, Kouyos RD, Hasse B, Zinkernagel AS, Trkola A, Manz MG, Abela IA, Müller AMS. Antibody Response to SARS-CoV-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jan 26:S2666-6367(22)00039-2. doi: 10.1016/j.jtct.2022.01.019. Online ahead of print. PMID: 35092892
• Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMoa2116596. Online ahead of print. PMID: 34904798
• Krieg S, Seeger H, Hofmann P, Del Prete C, Manz MG, Müller AM, Theocharides APA. Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia. Br J Haematol. 2022 Feb;196(3):781-784. doi: 10.1111/bjh.17854. Epub 2021 Oct 5. PMID: 34611894
• Ruder J, Rex J, Obahor S, Docampo MJ, Müller AMS, Schanz U, Jelcic I, Martin R. NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Front Immunol. 2021 Dec 16;12:794077. doi: 10.3389/fimmu.2021.794077. eCollection 2021. PMID: 34975899
• Rieger MJ, Stolz SM, Ludwig S, Benoit TM, Bissig M, Widmer CC, Schwotzer R, Müller AM, Nair G, Hegemann I, Manz MG, Schanz U. Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. Br J Haematol. 2021 Sep;194(5):931-934. doi: 10.1111/bjh.17655. Epub 2021 Jun 28. PMID: 34180543
• Linnik J, Syedbasha M, Kaltenbach HM, Vogt D, Hollenstein Y, Kaufmann L, Cantoni N, Ruosch-Girsberger S, Müller AMS, Schanz U, Müller Pabst T, Stüssi G, Weisser M, Halter J, Stelling J, Egli A. (2021) Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant (HSCT) patients. J Infect Dis. 2021 Aug 20. Online ahead of print. PMID: 34415049
• Diem-Lan Vu, Julie-Anne Dayer, Stavroula Masouridi-Levrat, Christophe Combescure, Elsa Boely, Nina Khanna, Nicolas J Mueller, Martina Kleber, Michael Medinger, Joerg Halter, Jakob Passweg, Antonia M Müller, Urs Schanz, Yves Chalandon, Dionysios Neofytos, Christian van Delden, Laurent Kaiser, Swiss Transplant Cohort Study (2020) Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5‐year analysis within the Swiss Transplant Cohort study. Transpl Infect Dis 22(4) Epub 2020 Apr 27 – IF 2.071
• Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nuñez N, Simonis A, Pfister S, Wilk CM, McHugh D, Friemel J, Müller AM, Becher B, Münz C, van den Broek M, Neri D, Manz MG (2020) Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34:2688-2703. Epub 2020 May 1 – IF 8.665
• Bögeholz J, Russkamp NF, Wilk CM, Gourri E, Haralambieva E, Schanz U, Mueller NJ, Manz MG, Müller AMS (2020) Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. Mar;26:581-592. – IF 3.853
• Müller AMS, Min D, Wernig G, Levy RB, Perez VL, Herretes S, Florek M, Burnett C, Weinberg K, Shizuru JA (2019) Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets. Biol Blood Marrow Transplant 25(12):2338-2349 – IF 3.853
• Guido Ghilardi, Beatrice Mueller, Barbara Jeker, Rouven Müller, Anne Cairoli, Antonia Müller, Mario Bargetzi, Felicitas Hitz, Dominik Heim, Adrian Schmidt, Davide Rossi, Michele Ghielmini, Luciano Wannesson, Erika Lerch, Panagiotis Samaras, Urs Schanz, J Passweg, Georg Stussi, Martina Kleber, Bernhard Gerber (2019) Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multi-centric observational registry study. Bone Marrow Transplant. 54(7):1029-1037 – IF 4.725
• Simonis A, Fux M, Nair G, Mueller NJ, Haralambieva E, Pabst T, Pachlopnik Schmid J, Schmidt A, Schanz U, Manz MG, Müller AMS (2018) Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literature. Ann Hematol. 97(10):1961-1973 – IF 2.904
• Samaras P, Rütti MF, Seifert B, Bachmann H, Schanz U, Eisenring M, Renner C, Susanne Müller AM, Schmidt A, Mischo A, Fuchs I, Bargetzi M, Manz MG, Stupp R, Petrausch U, Stenner-Liewen F. (2018) Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. Biol Blood Marrow Transplant. 24(4):694-699 – IF 3.853
• Mathew NR, Baumgartner F, Braun L, O´Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T,Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D (DH), Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R (2018) Sorafenib promotes graft-versus-eukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. Nature medicine, 24(3):282-291 – IF 36.130
• Passweg JR, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Güngör T, Halter J, Heim D, Hess U, Leibundgut U, Müller A, Nair G, Pabst T, Renner C, Stuessi G, Nicoloso de Faveri G, Schanz U for the Swiss Blood Stem Cell Transplantation Group (SBST). (2018) Hematopoetic Cell Transplantation in Switzerland, Changes and Results over 20 years. A report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation (SBST) Registry 1997-2016. Swiss Med Wkly, 148:w14589 – IF 1.822
• Wilk CM, Weber I, Seidl K, Rachmühl C, Holzmann-Bürgel A, Müller AM, Kuster SP, Schanz U, Zinkernagel AS (2017) Impact of oral gut decontamination on Staphylococcus aureus colonization in patients undergoing allogeneic hematopoietic stem cell transplantation International Journal of Antimicrobial Agents. Int J Antimicrob Agents, 50(6):726-729 – IF 4.621
• Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA (2016) Blood stem cell activity is arrested by T_H1-mediated injury preventing engraftment following non-myeloablative conditioning. Journal of Immunology, 197(10):4151-4162 – IF 4.886
• Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete. Clin Cancer Res 15;21(16):3727-39 – IF 10.107
• Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA (2014) Donor hematopoiesis in mice following total lymphoid irradiation requires host T regulatory cells for durable engraftment. Blood 123:2882-2892 – IF 17.794
• Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R (2014) Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation 124:2668-2682 – IF 11.864
• Filatenkov A, Baker J, Müller AM, Ahn G-O, Kohrt HE, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S (2014) Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion. Radiation Research 182:163-169 – IF 2.657
• Florek M, Sega EI, Leveson-Gower D, Baker J, Müller AM, Meyer E, Negrin RS (2014) Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Blood 124:1832-1842 – IF 17.794
• Ali SR, Ranjbarvaziri S, Talkhabi M, Subat A, Volz K, Zhao P, Müller AM, Red-Horse K, Weissman IL, Ardehali R (2014) Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circulation Research 115:625-635 – IF 14.467
• Müller AM, Shashidhar S, Küpper N, Kohrt HE, Florek M, Negrin R, Brown J, Shizuru JA (2012) Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proceedings of the National Academy of Sciences (PNAS) USA 109:5820-5825 – IF 9.412
• Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino A, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA (2012) Long-term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. Biology of Blood and Marrow Transplantation 18:125-133 – IF 3.853
• Kohrt HE, Müller AM, Baker J, Goldstein MJ, Newell E, Dutt S, Czerwinski D, Lowsky R, Strober S (2011) Donor immunization with WT1 peptide augments anti-leukemic activity after MHC-matched bone marrow transplantation. Blood 118:5319-5329 – IF 17.794
• Kohrt HE, Houot R, Goldstein M, Weiskopf K, Alizadeh AA, Brody J, Müller AM, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder T, Levy R (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423-2432 – IF 17.794
• Udi J, Wider D, Kleber M, Ihorst G, Müller AM, Wäsch R, Engelhardt M (2011) Endothelial progenitor cells, hemangioblasts and VEGFR2⁺-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments. Leukemia Research 35:1265-1268 – IF 2.214
• Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA (2010) Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences (PNAS) USA 107:14721-14726 – IF 9.412
• Filatenkov A, Müller AM, Tseng WW, Dejbakhsh-Jones S, Winer D, Luong R, Shizuru JA, Engleman EG, Strober S (2009) Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. Journal of Immunology 183:7196-7203 – IF 4.886
• Müller AM, Martens UM, Hofmann S, Bruckner-Tuderman L, Mertelsmann R, Lübbert M (2006) Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Annals of Hematology 85:1-16 – IF 2.904
• Müller AM, Ihorst G, Waller CF, Dolken G, Finke J, Engelhardt M (2006) Intensive chemotherapy with autologous peripheral blood stem cell transplantation during a 10-year period in 64 patients with germ cell tumor. Biology of Blood and Marrow Transplantation 12:355-365 – IF 3.853
• Müller AM, Geibel A, Neumann H, Kühnemund A, Schmitt-Gräff A, Böhm J, Engelhardt M. (2006) Primary (AL) amyloidosis in plasma cell disorders. The Oncologist 11:824-830 – IF 5.025

Reviews

• Luginbuehl V, Abraham E, Kovar K, Flaaten R, Müller AMS. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv. 2022 Feb 9:107917. doi: 10.1016/j.biotechadv.2022.107917.
• Roth P, Winklhofer S, Müller AMS, Dummer R, Mair MJ, Gramatzki D, Le Rhun E, Manz MG, Weller M, Preusser M. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 2021 Jun;97:102189. doi: 10.1016/j.ctrv.2021.102189. Epub 2021 Mar 23. PMID: 3387297
• Ring A, Müller AM (2019) Chemotherapie-freie Behandlung von hämatologischen Neoplasien: Zukunftstraum oder beginnende Realität? Praxis 2019; 108(6):1-9
• Müller AM, Duque J, Shizuru JA, Lübbert M (2008) Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 27:5759-577 – IF 7.971
• Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Annals of Hematology 84:1-12 – IF 2.904
• Müller AM, Rawluk J, Thierry V, Brink I, Engelhardt M (2005) Innovative antibody-therapies for malignant lymphomas. Deutsche Medizinische Wochenschrift 130:2783-2788 – IF 0.569
• Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L (2007). Bullous pemphigoid associated with hypereosinophilic syndrome: Simultaneous response to imatinib. Journal of the American Academy of Dermatology 56:S68-72 – IF 8.277

Case reports / Letters to the editor

• Koch C, Montrasio G, Scherr B, Schimmer R, Matter C, Bühler K, Manz MG, Müller AM. Fulminant Cardiotoxicity in a Patient with Cardiac Lymphoma Treated with CAR-T Cells. JACC Cardio Oncology, in press
• Rösler W, Bink A, Bissig M, Imbach L, Marques Maggio E, Manz MG, Müller T, Roth P, Rushing E, Widmer C, Zenz T, von Moos S, Müller AMS. CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS. Hemasphere. 2022 Jun 17;6(7):e733. doi: 10.1097/HS9.0000000000000733. eCollection 2022 Jul
• Utebay D, Seeger H, Müller AMS, David S. Complement inhibition for the treatment of COVID-19 triggered thrombotic microangiopathy with cardiac failure: a case report. Eur Heart J Case Rep. 2021 Sep 28;5(10):ytab386. doi: 10.1093/ehjcr/ytab386. eCollection 2021 Oct. PMID: 34661055
• Doerschner M, Pekar-Lukacs A, Messerli-Odermatt O, Dommann-Scherrer C, Rütti M, Müller AM, Nair G, Kamarachev J, Kerl K, Beer M, Messerli M, Frauenknecht K, Haralambieva E, Hoetzenecker W, French LE, Guenova E (2018) Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Br J Dermatol. 181(6):1296-1302 – IF 8.277
• Wehrli M, Oppliger Leibundgut E, Gattiker HH, Manz MG, Müller AM*, Goede JS* (*shared last authorship) (2017) Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. Oncologist. 22(4):480-483 – IF 5.025
• Kiesel H, Müller AM, Schmitt-Graeff A, Veelken H (2009) Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations. (Bench-to-Bedside Report) Cancer Biology & Therapy 8:319-321 – IF 3.659
• Engelhardt M, Müller AM, Maier W, Wäsch R (2005) Severe irreversible bilateral hearing loss after bortezomib (VELCADE(R)) therapy in a multiple myeloma (MM) patient. (Correspondence) Leukemia 19:869-870 – IF 8.665
• Müller AM, Betz MJ, Kromeier J, Ghanem NA, Geibel A, Imdahl A, Frydrychowicz AP (2006) Acute pneumopericardium due to intestino-pericardial fistula. (Images in cardiovascular medicine) Circulation 114:e7-9 – IF 23.603

Book Chapters

• Müller AM, Florek M (2014) 5-Azacytidine/ Azacitidine. In: Recent Results in Cancer Research: Small Molecules in Oncology. Martens, U.M. (eds), pp. 299-324, Springer Berlin Heidelberg.
• Müller A, Zürcher G. (2008) Nutrition in Cancer Patients. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 225-234, Springer. Heidelberg Berlin New York
• Müller A, Scheele J. (2008) Inhibition of Angiogenesis. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 319-321, Springer. Heidelberg Berlin New York
• Scheele JS, Müller A, Martens U. (2008) Pharmacogenetics and Pharmacogenomics. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 201-203, Springer. Heidelberg Berlin New York
• Thierry V, Müller A, Engelhardt M, (2008) Growth Factors. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 218-224, Springer. Heidelberg Berlin New York

Editorials, other publication types

• Müller AMS (2022). Chronic GVHD on the Move, Blood à accepted, in press
• Müller AMS, Kumar SK, Bruno B (2019) The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all? Haematologica 104(2):222-225. (Editorial)
• Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A (2016) Holbrook Kohrt: In Memoriam (1977-2016). Clinical Cancer Research 22:3695-3696

Positions and Functions

• from 05/2022: Medical University of Vienna and General Hospital Vienna; University Professor for Cellular Therapy and Transfusion Medicine; Chair of the Department of Blood Group Serology and Transfusion Medicine
• 04/2012-04/2022: University Hospital Zurich and University Zurich
• 01/2020-04/2022: Senior attending with extended responsibilities in Medical Oncology and Hematology
• 06/2015-12/2019: Senior attending in Medical Oncology and Hematology, Stem cell transplantation / Cellular therapies
• Since 2018: Establishment and lead of CAR-T cell program
• 03/2017-04/2022: Medical head of clinical stem cell laboratory; Program director of autologous stem cell transplantation program
• 04/2016-04/2022: Establishment of a specialized, interdisciplinary clinic for patients with chronic Graft-versus-Host Disease

Clinical Education

• 08/2014: Board examination in Internal Medicine, Hematology and Oncology (Germany: Internistische Hämatologie & Onkologie)
• 04/2012-12/2014: Clinical Fellowship Hematology, University Hospital Zurich
• 06/2002-12/2005: Residency Internal Medicine, University Medical Center Freiburg, Department of Hematology/Oncology, Chair: Prof. R. Mertelsmann
• 1995-2002: Candidate for M.D., School of Medicine, Albert-Ludwigs University, Freiburg; Germany

Experimental and Clinical Research

• 11/2017: Habilitation in Hematology, “Friend or foe? – Donor T cells regulate hematopoietic stem cell and immune function following allogeneic hematopoietic cell transplantation”
• 2016 to 2022: Clinical study activities as «Local Principal Investigator”, mostly in the context of cellular therapies
• 01/2013 to 2022: Group leader in the Experimental Hematology Laboratory, University Hospital Zurich:
• 01/2010 to 03/2012: Research Associate, Division of Blood & Marrow Transplantation, Stanford University
• 2006 to 2009: Postdoctoral Fellowship: Division of Blood & Marrow Transplantation, Stanford University; Supervisor: Prof. J.A. Shizuru
• 1998-2002: Dissertation / ME thesis: Gene expression of annexin II and ribosomal protein LP23A and cytokine analysis in juvenile myelomonocytic leukemia. University Children’s Hospital Zurich, Hematology, thesis advisor Prof C.N. Niemeyer

Honors, awards, grants

• 2020: Basic Science Award of the European Society of Blood and Marrow Transplantation (EBMT) – “JUN activation in dermal fibroblasts promotes fibrosis and inflammation in sclerodermatous graft-vs-host disease in mice and humans”
• 2017: Support from the Swiss Transplant Cohort Study (STCS); project: Reconstitution of T cell immunity against cytomegalovirus (CMV) following allogeneic hematopoietic cell transplantation (HCT)
• 2017: Best Abstract Award at the Annual Meeting of the DGHO/OeGHO/SGMO und SGH (“Alloreactivity targets the bone marrow microenvironment following allogeneic hematopoietic cell transplantation”)
• 2015: Support from the PROMEDICA Foundation: “Wissenschaftliche Oberarztstelle” for 2 years: start 04/2016 (80% protected research time)
• 2014: Cancer League Zurich, Project funding “Intestinal microbial changes in patients with acute leukemias during chemotherapy”
• 2014: URPP (University Research Priority Program), Translational Cancer Research: “Reconstitution of blood & immune function, GVHD-, and GVL-effects – unraveling the complex relationships in the bone marrow after blood stem cell transplantation”
• 2014: SFK / Stiftung zur Förderung der Knochenmarktransplantation - Candy Heberlein Award; “Complex Interactions following allogeneic hematopoietic cell transplantation – Immunefunction, pharmacological immunosuppression, GVHD and CMV-reactivation”
• 2014: Transplantation-Center University Hospital Zurich: Award for best scientific experimental publication in transplantation
• 2014: Kurt & Senta Hermann Foundation: Project Funding “Reconstitution of blood formation and immune function, graft-vs-host disease and graft-vs-leukemia effects”
• 2013 to 2016: Project funding by the Swiss Cancer League for “Improving Graft-versus-tumor Effects by Donor Vaccination with WT1-peptide and Transplantation of Tailored Hematopoietic Grafts”
• 2006 to 2007: Postdoctoral Research Fellowship, German Research Foundation (“Murine models of chronic Graft-vs-Host Disease”)

Selected Memberships

• American Society of Hematology (ASH)
• European Hematology Association (EHA)
• Walter Siegenthaler Gesellschaft
• American Society of Transplantation and Cellular Therapies (ASTCT)
• Swiss Society of Hematology (SSH)
• Österreichische Gesellschaft für Blutgruppenserologie, Transfusionsmedizin, Regenerative Medizin und Immungenetik (ÖGBT)
• Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)

• Leitung Erythrozytenlabor und Hämogenetik

• Leitung Granulozytenlabor

• Immunhämatologie
• Granulozytenimmunologie
• Hämogenetik

• Immunhämatologie
• Hämogenetik
• Allo- und Autoimmunisierung
• Granulozytenimmunologie
• Entzündungsmechanismen
• Transplantationsimmunologie
• Qualitätsmanagement
• universitäre Lehre

• Leitung Therapeutische Apheresen

• Leitung Zell- & Gewebeentnahmeeinrichtung und Gewebebank

• Herstellungsleitung ATMP

• Therapeutische Apheresen
• Stammzellmobilisierung & Stammzellsammlung
• Therapie mit Immuneffektorzellen inkl. CAR-T Zellen

• Optimierung der Stammzellmobilisation
• extrakorporale Photopherese in der Therapie der GvHD und Organtransplantation
• CAR-T Zellen

Original papers

• 102. Infanti L, Leitner G, Moe MK, Pehlic V, Benkert P, Cattaneo M, Holbro A, Passweg J, Worel N, Buser A. Indices of iron homeostasis in asymptomatic subjects with HFE mutations and moderate ferritin elevation during iron removal treatment. Blood Cells Mol Dis. 2022 Jun 26;97:102689. doi: 10.1016/j.bcmd.2022.102689. PMID: 35780678
• 101. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.Haematologica. 2022 May 1;107(5):1045-1053.
• 100. Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakih RE, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge PW, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M. Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.Transplant Cell Ther. 2022 Apr 10:S2666-6367(22)01198-8. doi: 10.1016/j.jtct.2022.04.003. PMID: 35413459.
• 99. Gökler J, Aliabadi-Zuckermann A, Zuckermann A, Osorio E, Knobler R, Moayedifar R, Angleitner P, Leitner G, Laufer G, Worel N. Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients-A Pilot Study.Transpl Int. 2022 Mar 23;35:10320. doi: 10.3389/ti.2022.10320. eCollection 2022. PMID: 35401042.
• 98. Porpaczy E, Wohlfarth P, Königsbrügge O, Rabitsch W, Skrabs C, Staber P, Worel N, Müllauer L, Simonitsch-Klupp I, Kornauth C, Rohrbeck J, Jaeger U, Schiefer AI. Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers (Basel). 2021 Nov 9;13(22):5592.
• 97. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403-1415.
• 96. Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT; Worldwide Network for Blood & Marrow Transplantation. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. Transplant Cell Ther. 2021 Mar;27(3):270.e1-270.e6. Epub 2020 Dec 15.
• 95. Oberbauer R, Edinger M, Berlakovich G, Kalhs P, Worel N, Heinze G, Wolzt M, Lion T, Wekerle T. A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001).Front Med (Lausanne). 2021 Jan 27;7:634260. eCollection 2020.
• 94. Benazzo, A., Worel, N., Schwarz, S., Just, U., Nechay, A., Lambers, C., Böhmig, G., Fischer, G.b, Koren, D., Muraközy, G., Knobler, R., Klepetko, W., Hoetzenecker, K., Jaksch, P. Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients. Transfus Med Hemother. 2020 Jun;47(3):205-213
• 93. Goekler, J., Zuckermann, A., Worel, N., Ceran, E., Kaiser, P., Neuber, N., Laufer, G., Aliabadi-Zuckermann, A. Extracorporeal Photopheresis Immediately after Heart Transplantation in High Risk Patients. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2020, 39(4), pp. S229.
• 92. Greinix, H.T., Attarbaschi, A., Girschikofsky, M., Greil, R., Holter, W., Neumeister, P., Peters, C., Petzer, A., Rudzki, J., Schlenke, P., Schmitt, C.A., Schwinger, W., Wolf, D., Worel, N., Jaeger, U Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. Memo - Magazine of European Medical Oncology. 2020;13(1), pp. 27-31
• 91. Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020 Apr;55(4):681-694.
• 90. Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018 Oct 20;18(1):1008.
• 89. Worel N, Lehner E, Führer H, Kalhs P, Rabitsch W, Mitterbauer M, Hopfinger G, Greinix HT. Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? Transfusion. 2018 Apr;58(4):1045-1053.
• 88. Holbro A, Baldomero H, Lanza F, Chabannon C, Snowden JA, Buser A, Infanti L, Worel N, Sureda A, Badoglio M, Passweg J, Bonini C; Cellular Therapy & Immunobiology Working Party of the European Society for Blood & Marrow Transplantation (EBMT) and the Joint Accreditation Committee International Society for Cellular Therapy & EBMT (JACIE). Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. Cytotherapy. 2018 Mar;20(3):453-460.
• 87. Morton S, Stanworth S, Lozano M, Harrison SJ, Hong FS, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner JM, Yokoyama APH, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use. Vox Sang. 2017 Oct;112(7):e48-e68.
• 86. Morton S, Stanworth S, Lozano M, Harrison SJ, Hong FS, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner JM, Yokoyama APH, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sang. 2017 Oct;112(7):680-683.
• 85. Worel N, Frank N, Frech C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017 Sep;57(9):2206-2215
• 84. Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C, Mohty M. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017 Oct;52(10):1367-1371.
• 83. Worel N, Fritsch G, Agis H, Böhm A, Engelich G, Leitner GC, Geissler K, Gleixner K, Kalhs P, Buxhofer-Ausch V, Keil F, Kopetzky G, Mayr V, Rabitsch W, Reisner R, Rosskopf K, Ruckser R, Zoghlami C, Zojer N, Greinix HT.Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher. 2017 Aug;32(4):224-234.
• 82. Dmytrus J, Matthes-Martin S, Pichler H, Worel N, Geyeregger R, Frank N, Frech C, Fritsch G. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant. 2016 Aug;51(8):1093-100.
• 81. Fritsch G, Frank N, Dmytrus J, Frech C, Pichler H, Witt V, Geyeregger R, Scharner D, Trbojevic D, Zipperer E, Printz D, Worel N. Relevance of flow cytometric enumeration of post-thaw leucocytes: influence of temperature during cell staining on viable cell recovery. Vox Sang. 2016 Aug;111(2):187-96.
• 80. Bojic M, Worel N, Sperr WR, Schellongowski P, Wohlfarth P, Schwarzinger I, Mitterbauer-Hohendanner G, Fischer G, Dieckmann KU, Lamm W, Leiner M, Schulenburg A, Mitterbauer M, Greinix HT, Kalhs P, Rabitsch W. Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation. Oncology. 2016;90(3):160-6.
• 79. Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90.
• 78. Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, Shaw BE, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biol Blood Marrow Transplant. 2016 Jan;22(1):96-103
• 77. Worel N, Buser A, Greinix HT, Hägglund H, Navarro W, Pulsipher MA, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, Niederwieser D, van Walraven SM, Rocha V, Torosian T, Vergueiro C, Weisdorf D, Yabe H, Halter JP. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2015 Dec;21(12):2052-60.
• 76. Lamm W, Wohlfarth P, Bojic M, Schörgenhofer C, Drach J, Gisslinger H, Worel N, Schiefer A, Schulenburg A, Agis H, Kalhs P, Greinix HT, Schellongowski P, Rabitsch W. Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. Oncology. 2015;89(4):196-204
• 75. Leitner GC, Kolovratova V, Horvath M, Worel N. Granulocyte collection using a novel apheresis system eases the procedure and provides concentrates of high quality. Transfusion. 2015 May;55(5):991-5.
• 74. Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, Apperley J, Edinger M, Hauser A, Mischak-Weissinger E, Dickinson AM, Lowdell MW. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy. 2014 Mar;16(3):289-97.
• 73. Boehm A, Sperr WR, Kalhs P, Greinix H, Valent P, Worel N, Kainz A, Mitterbauer M, Bojic M, Rabitsch W. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. Wien Klin Wochenschr. 2014 Jan;126(1-2):23-9.
• 72. Repa A, Mayerhofer M, Worel N, Cardona F, Deindl P, Pollak A, Berger A, Haiden N. Blood transfusions using 27 gauge PICC lines: a retrospective clinical study on safety and feasibility. Klin Padiatr. 2014 Jan;226(1):3-7.
• 71. Wohlfarth P, Ullrich R, Staudinger T, Bojic A, Robak O, Hermann A, Lubsczyk B, Worel N, Fuhrmann V, Schoder M, Funovics M, Rabitsch W, Knoebl P, Laczika K, Locker GJ, Sperr WR, Schellongowski P; Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin (ÖGIAIN). Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. Crit Care. 2014 Jan 20;18(1):R20.
• 70. Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014 Jul;49(7):865-72.
• 69. Rabitsch W, Böhm A, Bojic M, Schellongowski P, Wöhrer S, Sliwa T, Keil F, Worel N, Greinix H, Hauswirth A, Kalhs P, Jaeger U, Valent P, Sperr WR. Clofarabine/cyclophosphamide for debulking before stem cell transplantation. Eur J Clin Invest. 2014 Aug;44(8):775-83.
• 68. Das-Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Jagasia M. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica. 2014 Nov;99(11):1746-1752.
• 67. Worel N, Knöbl P, Karanikas G, Fuchs EM, Bojic A, Brodowicz T, Jilma P, Zielinski CC, Köstler WJ, Locker GJ. Hepatic dysfunction contributes to coagulation disturbances in pts undergoing whole body hyperthermia by use of extracorporeal circulation. Int J Artif Organs. 2014 Sep 20;37(9):715-726.
• 66. Leitner GC, Kolovratova V, Horvath M, Worel N. Granulocyte collection using a novel apheresis system eases the procedure and provides concentrates of high quality. Transfusion. 2014 Nov 21
• 65. Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D.Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).Bone Marrow Transplant. 2013 Feb;48(2):220-5.
• 64. Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G.Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013 Jul;19(7):1129-33.
• 63. Repa A, Mayerhofer M, Cardona F, Worel N, Deindl P, Pollak A, Berger A, Haiden N. Safety of blood transfusions using 27 gauge neonatal PICC lines: an in vitro study on hemolysis. Klin Padiatr. 2013 Dec;225(7):379-82.
• 62. Hejna M, Birner P, Preusser M, Thallinger CM, Worel N, Asari R, Dolak W, Schmid R, Schoppmann SF, Raderer M. Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. Mol Clin Oncol. 2013 Nov;1(6):1079-1083.
• 61. Worel N, Apperley J, Basak G, Douglas K, Gabriel I, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Duarte R, Mohty M. European Data on Stem Cell Mobilization with Plerixafor in Patients with Non-Hematologic Diseases: An Analysis of the European Consortium of Stem Cell Mobilization. Transfusion. 2012 Nov;52(11):2395-400.
• 60. Auer-Hackenberg, L., Staudinger, T., Bojic, A., Locker, G., Leitner, G.C., Graninger, W., Winkler, S., Ramharter, M., Worel, N. Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: A retrospective cohort study. Malaria Journal. 2012;Volume 11,Article number 158.
• 59. Kolovratova V, List J, Worel N, Jilma P, Leitner G. Administration of Prednisolone intravenously or Dexamethason orally in random donors reveals equal results in granulocyte collection: a single centre experience. Vox Sang. 2012 Jul;103(1):75-8.
• 58. Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2012 Aug;47(8):1046-50.
• 57. Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant. 2012 Feb;18(2):314-7.
• 56. Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant. 2012 Jul;47(7):1003-5.
• 55. Locker GJ, Fuchs EM, Worel N, Bojic A, Heinrich G, Brodowicz T, Clodi M, Funk GC, Knöbl P, Zielinski CC, Köstler WJ. Whole body hyperthermia by extracorporeal circulation in spontaneously breathing sarcoma patients Hemodynamics and oxygen metabolism. Int J Artif Organs. 2011 Nov;34(11):1085-94.
• 54. Kuzmina Z, Eder S, Böhm A, Pernicka E, Vormittag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R, Just U, Krenn K, Worel N, Greinix HT. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2011 Sep 16.
• 53. Rosskopf K, Ragg SJ, Worel N, Grommé M, Preijers FW, Braakman E, Schuurhuis GJ, van Riet I, Wendel S, Fontão-Wendel R, Lazar A, Goldman M, Halpenny M, Giulivi A, Letcher B, McGann L, Korhonen M, Arvola A, Humpe A, Buwitt-Beckmann U, Wiesneth M, Schauwecker P, Schrezenmeier H, Bönig H, Henschler R, Seifried E, Accorsi P, Bonfini T, Takanashi M, van Beckhoven JM, Brand A, Gounder D, Wong A, Dooccey R, Forrest E, Galea G, Smythe J, Pawson R, Reems JA, Oh J, Reesink HW, Panzer S. Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow). Vox Sang. 2011 Oct;101(3):255-75.
• 52. Boehm A, Rabitsch W, Locker GJ, Worel N, Robak O, Laczika KF, Staudinger T, Bojic A, Siersch V, Valent P, Sperr WR. Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. Wien Klin Wochenschr. 2011 Jun;123(11-12):354-8.
• 51. Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant. 2011 Feb 28.
• 50. Boehm A, Walcherberger B, Sperr WR, Wöhrer S, Dieckmann K, Rosenmayr A, Pernicka E, Fischer G, Worel N, Mitterbauer G, Schwarzinger I, Mitterbauer M, Haas OA, Lechner K, Hinterberger W, Valent P, Greinix HT, Rabitsch W, Kalhs P. Improved outcome in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: A single center experience. Biol Blood Marrow Transplant. 2011 Jan;17(1):133-40.
• 49. D’Addio A, Worel N, Motta MR, Rizzi S, Dan E, Taglioli S, Giudice V, Agis H, Kopetzky G, Douglas K, Baccarani M, Lemoli RM. The addition of Plerixafor allows adequate PBSC collection in Multiple Myeloma and Lymphoma patients poor–mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011;46(3):356-63.
• 48. Worel N, Böhm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, Mayr WR, Schwartz D, Greinix HT. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. Transfusion. 2011 Dec 1.
• 47. Greinix HT, Worel N, Knobler R. Role of Extracorporeal Photopheresis (ECP) in the treatment of steroid-refractory acute Graft-versus-Host disease. Biol Blood Marrow Transplant. 2010 Dec;16(12):1747-8.
• 46. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 2010 Sep 28
• 45. Leitner GC, Dettke M, List J, Worel N, Weigel G, Fischer MB. Red blood units collected from bone marrow harvests after mononuclear cell selection qualify for autologous use. Vox Sang. 2010 pr;98(3 PT 1):e284-9. Epub 2010 Jan 4.
• 44. Worel N, Panzer S, Reesnik HW, Linkesch W, Dickmeiss E, Fischer-Nielsen A, Hölig K, Stachel D, Zimmermann R, Holter W, Coluccia P, Brilhante D, Watz E, Sigle JP, Gratwohl A, Buser A, Arslan O, Regan F, Edwards M. Transfusion policy in ABO-incompatible allogeneic stem cell transplantation. Vox Sang. 2010;98:455-67.
• 43. Mayerhofer M, Haushofer A, Kyrle PA, Chott A, Müllner C, Quehenberger P, Worel N, Traby L, Eichinger S. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest. 2009;39(9):833-6.
• 42. Kuzmina Z, Greinix HT, Knobler R, Worel N, Kouba M, Weigl R, Körmöczi U, Rottal A, Pohlreich D, Zielinski C, Pickl WF. Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic GVHD. Blood. 2009;114(3):744-6.
• 41. Leitner GC, Baumgartner K, Kalhs P, Biener D, Greinix HT, Hoecker P, Worel N. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study. Bone Marrow Transplant. 2009;43(5):357-63.
• 40. Seidel MG, Minkov M, Witt V, Matthes-Martin S, Pötschger U, Worel N, Leitner G, Stary J, Gadner H, Peters C. Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol. 2009;31(3):166-72.
• 39. Boehm A, Sperr WR, Leitner G, Worel N, Oehler L, Jaeger E, Mitterbauer M, Haas OA, Valent P, Kalhs P, Rabitsch W. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest. 2008;38(12):945-52.
• 38. Worel N, Bojic A, Binder M, Jaksch P, Mitterbauer G, Streubel B, Thalhammer F, Staudinger T, Laczika KF, Locker GJ. Catastrophic graft-versus-host disease after lung transplantation proven by PCR-based chimerism analysis. Transpl Int. 2008;21(11):1098-101.
• 37. Worel N, Leitner G, Wagner A, Greinix HT, Höcker P, Kahls P. Therapeutic apheresis in hematopoietic cell transplantation. Turk J Hematol 2008;25:164-71.
• 36. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, Elandt K, Krainer M. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007;67(4):427-32.
• 35. Schmid, K.E., Worel, N., Höcker, P., Binder, S. Extracorporal rheohaemapheresis for age related macular degeneration: Preliminary experience in 4 patients. Spektrum d. Augenheilkunde. 2007, Volume 21, Issue 4, Pages 240-242
• 34. Leitner GC, Koszik F, Rudnicki T, Buchta C, Worel N, Fischer MB, Schneeberger A, Hoecker P. Apheresis products of the Amicus and the AS.TEC 204 cell separators are comparable with regard to dendritic cells derived from the mononuclear cell collection. Vox Sang. 2007;92(1):37-41.
• 33. Worel N, Greinix HT, Supper V, Leitner G, Mitterbauer M, Rabitsch W, Fischer G, Rosenmayr A, Höcker P, Kalhs P. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion. 2007;47(8):1494-502.
• 32. Worel N, Greinix HT, Leitner G, Mitterbauer M, Rabitsch W, Rosenmayr A, Höcker P, Kalhs P. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci. 2007;36(3):297-304.
• 31. Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr. 2006;118(1-2):49-53.
• 30. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P, Mitterbauer M, Rabitsch W, Schulenburg A, Kalhs P. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91(3):405-8.
• 29. Buchta C, Dettke M, Funovics PT, Höcker P, Knöbl P, Macher M, Quehenberger P, Treitl C, Worel N. Fibrin sealant produced by the CryoSeal FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting. Vox Sang. 2004; 86(4):257-62.
• 28. Buchta C, Dettke M, Funovics PT, Hirschl AM, Macher M, Worel N, Höcker P. Impact of manufacturing, irradiation and filtration steps to bacterial contamination of autologous fibrin sealant. Biologicals. 2004;32(3):165-9.
• 27. Rabitsch W, Knöbl P, Prinz E, Keil F, Greinix H, Kalhs P, Worel N, Jansen M, Hörl WH, Derfler K. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant. 2003;32(10):1015-9.
• 26. Kaufmann H, Ackermann J, Greinix H, Nösslinger T, Gisslinger H, Keck A, Ludwig H, Worel N, Kalhs P, Zielinski C, Drach J. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features. Ann Oncol. 2003;14(11):1667-72.
• 25. Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A, Mitterbauer M, Mannhalter C, Mayr WR, Schwarzinger I, Höcker P, Lechner K, Greinix HT. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion. 2003;43(8):1153-61.
• 24. Keil F, Prinz E, Moser K, Mannhalter C, Kalhs P, Worel N, Rabitsch W, Schulenburg A, Mitterbauer M, Greinix H. Rapid establishment of long-term culture-initiating cells of donor origin after NMA allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation.2003;76(1):230-6.
• 23. Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A, Höcker P, Dieckmann K, Fischer G, Rosenmayr A, Linkesch W, Hinterberger W, Lechner K, Greinix HT. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(9):619-26.
• 22. Worel N, Greinix HT, Keil F, Mitterbauer M, Lechner K, Fischer G, Mayr W, Höcker P, Kalhs P. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion. 2002;42(10):1293-301.
• 21. Keil F, Prinz E, Kalhs P, Lechner K, Moser K, Schwarzinger I, Jäger U, Fonatsch C, Worel N, Mannhalter C, Rabitsch W, Loidolt H, Schulenburg A, Mitterbauer M, Höcker P, Greinix HT. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia. 2001;15(3):355-61.
• 20. Worel N, Greinix H, Ackermann J, Kaufmann H, Urbauer E, Höcker P, Gisslinger H, Lechner K, Kalhs P, Drach J. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol. 2001;80(6):345-8.
• 19. Dettke M, Greinix HT, Kalhs P, Kührer I, Worel N, Höcker P. Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest. Transfusion. 2001;41(5):681-6.
• 18. Worel N, Kurz M, Peters C, Höcker P. Serial granulocytapheresis under daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. Transfusion. 2001; 41(3):390-5.
• 17. Keil F, Mitterbauer G, Chen X, Haas OA, Kalhs P, Lechner K, Mannhalter C, Moser K, Worel N, Pirc-Danoewinata H, Louda N, Loidolt H, Rabitsch W, Greinix HT. PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR. Transfusion. 2001;41(1):111-6.
• 16. Worel, N., Keil, F., Greinix, H., Kalhs, P., Höcker, P. Delayed massive immune hemolysis after minor ABO incompatible stem cell transplantation. Infusionstherapie und Transfusionsmedizin (from 1992 to 2002, continued as Transfusion Medicine and Hemotherapy); 2001,28(SUPPL. 1), pp. 23.
• 15. Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol. 2000;79(7):374-7.
• 14. Keil, F., Louda, N., Chen, X., Karlik, H., Kalhs, P., Worel, N., Rabitsch, W., Lechner, K., Greinix, H. Expansion of bcr-abl negative progenitor cells in LTBMC by MIP-la, SCF, IL-3 and IL-6. Blood. Volume 96, Issue 11 PART II, 2000, pp 121b.
• 13. Worel, N., Keil, F., Kalhs, P., Biener, D., Mitterbauer, M., Rabitsch, W., Hoecker, P., Lechner, K., Greinix, H. Long term outcome of patients who are alive and in complete remission two years after allogeneic stem cell transplantation. Blood. Volume 96, Issue 11, PART I, 2000, pp. 202a.
• 12. Schulenburg A, Kalhs P, Worel N, Höcker P, Knöbl P, Greinix HT. Immunologic recovery of patients given CD34-selected peripheral blood progenitor cell transplantation for malignant diseases. Bone Marrow Transplant. 2000;25(2):223-4.
• 11. Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knöbl P, Reiter E, Derfler K, Fischer G, Hinterberger W, Höcker P, Kalhs P. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion. 2000;40(5):543-50.
• 10. Reiter E, Greinix HT, Keil F, Brugger S, Rabitsch W, Schulenburg A, Mannhalter C, Schwarzinger I, Worel N, Volc-Platzer B, Fischer G, Dieckmann K, Hinterberger W, Schneider B, Haas OA, Geissler K, Kalhs P. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol. 1999;78(11):507-13.
• 9. Peters C, Minkov M, Matthes-Martin S, Pötschger U, Witt V, Mann G, Höcker P, Worel N, Stary J, Klingebiel T, Gadner H. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol. 1999;106(3):689-96.
• 8. Keil F, Kalhs P, Chen X, Haas OA, Fritsch G, Chott A, Lechner K, Moser K, Ackermann J, Rabitsch W, Worel N, Mannhalter C, Greinix HT. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation. Ann Hematol. 1999;78(8):376-9.
• 7. Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G, Worel N, Lechner K, Greinix HT. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol. 1999;78(4):189-91.
• 6. Reiter, E., Greinix, H.T., Mitterbauer, G., Fischer, G., Keil, F., Mannhalter, C., Rabitsch, W., Schwarzinger, I., Worel, N., Lechner, K., Kalhs, P. Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia. Annals of Hematology. 1998;Volume 77, Issue 6, Pages 283-286.
• 5. Dettke M, Hlousek M, Kurz M, Leitner G, Rosskopf K, Stiegler G, Stohlawetz P, Worel N, Höcker P, Panzer S. Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion. 1998 May;38(5):449-53.
• 4. Höcker P, Kührer I, Worel N, Leitner G, Kalhs P, Greinix H, Gerhartl K. Positive selection of CD34+ cells by immune affinity. Beitr Infusionsther Transfusionsmed. 1997;34:166-70.
• 3. Worel, N., Greinix, H., Kalhs, P., Kührer, I., Zelenka, P., Schmidt, H., Höcker, P. Collection of peripheral blood stem cells (PBSC) from patients with multiple myeloma (MM) and autologous transplantation. Infusionstherapie und Transfusionsmedizin (from 1992 to 2002, continued as Transfusion Medicine and Hemotherapy) Volume 24, Issue 4, 1997, Page 238.
• 2. Worel N, Peters C, Gerhartl K, Wagner A, Jurko S, Höcker P. Collection of peripheral blood stem cells (PBSC) after chemotherapy and administration of rhGM-CSF in children weighing less than 17 kg. Transfus Sci. 1996;17(4):601-6.
• 1. Heinz, R., Fortelny, A., Schneider, B., Hopfinger, G., Worel, N., Möstl, M., Waldner, R., Tüchler, H., Pittermann, E., Hanak, H. Long-term follow-up of 1,654 consecutive non-hodgkin lymphoma patients-data from a single institution. Oncology Research and Treatment. 1995;18(3), pp. 231-239.

Reviews/Editorial/Commentaries

• 18. Nina Worel, Mahmoud Aljurf, Chloe Anthias, Andreas S Buser, Meghann Cody, Mirjam Fechter, Sebastian Galeano, Hildegard T Greinix, Annika M Kisch, Mickey B C Koh, Thilo Mengling, Grazia Nicoloso, Dietger Niederwieser, Michael A Pulsipher, Adriana Seber, Bronwen E Shaw, Heather E Stefanski, Galen E Switzer, Jeff Szer, Suzanna M van Walraven, Hung Yang, Jörg P Halter. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. The lancet haematology in press.
• 17. Buser A, Worel N. Extracorporeal Phototherapy. Transfus Med Hemother. 2020 Jun;47(3):197
• 16. Hopfinger G, Worel N. CAR T-cell therapy in diffuse large B-cell lymphoma. Memo - Magazine of European Medical Oncology. 2020;13(1), pp. 32-35.
• 15. Humpe, A., Körper, S., Schäfer, R., Klump, H., Worel, N. The Role of Transfusion Medicine Departments in the Process of Implementing Approved CAR-T Cell Therapies. Tumor Diagnostik und Therapie. 2019, 40(10), pp. 672-676.
• 14. Worel N, Mansouri Taleghani B, Strasser E. Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology. Transfus Med Hemother. 2019 Dec;46(6):394-406. doi: 10.1159/0
• 13. Hopfinger G, Jäger U, Worel N. CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. Hemasphere. 2019 Mar 8;3(2):e185. doi: 10.1097/HS9.0000000000000185.
• 12. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor T‑cell therapy—a hematological success story. Memo - Magazine of European Medical Oncology. 2018;11(2), 116-121
• 11. Worel N. Practical implementation - Essential elements resource tool. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):198-202.
• 10. Worel N. ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. Transfus Med Hemother. 2016 Jan;43(1):3-12.
• 9. Greinix HT, Worel N, Just U, Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci. 2014 Jun;50(3):349-57.
• 8. Greinix, HT, Mitterbauer M, Rabitsch W, Worel N, Just U, Knobler R, Kalhs P. New developments in acute graft-versus-host disease. Memo - Magazine of European Medical Oncology. 2013, 6(2), pp. 98-101.
• 7. Auer-Hackenberg, L., Winkler, S., Graninger, W., Worel, N., Ramharter, M. Current evidence and future of automated erythrocyte exchange in the treatment of severe malaria. Wiener Klinische Wochenschrift. 2012,124(3 SUPPL.), 23-26
• 6. Worel N, Leitner GC. Clinical results of extracorporeal photopheresis. Transfusion Medicine and Hemotherapy. 2012,39(4),254-262
• 5. Worel N. Plerixafor – the magic bullet in stem cell mobilization failure? Editorial. Leuk Res. 2011 Feb 2.
• 4. Leitner GC, Worel N, Vogelsang H. Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. Transfusion Medicine and Hemotherapy. 2010, 39(4),246-252
• 3. Greinix HT, Worel N. New agents for mobilizing peripheral blood stem cells. Transfus Apher Sci. 2009;41(1):67-71.
• 2. Worel N, Mayr W. Stem cell harvesting and transplantation. ISBT Science Series 2009;4:193-99.
• 1. Worel N, Kalhs P. AB0-incompatible allogeneic hematopoietic stem cell transplantation. Haematologica. 2008;93(11):1605-7.

Buch/Buchkapitel

• Editor von Best Practices of Apheresis in hematopoietic Cell Transplantation aus der Serie “Advances and Controversies in Hematopoietic Transplantation and Cell Therapy”
• Chapter 5: Mobilization Strategies: HPC(A) Collections for Autologous Hematopoietic Cell Transplants (Seite 51 bis 63), 2020, ISBN 978-3-319-55130-2
• Establishing a Hematopoietic Stem Cell Transplantation Unit
• Chapter 10: Donor/Recipient Selection, Work Up and Safety, 2018, ISBN 978-3-319-59356-2
• Extracorporeal Photopheresis Cellular Photoimmunotherapy
• Chapter 2: ECP in Patients with Bleeding Risks (Seite 22 bis 28), 2012, ISBN 978-3-11-027594-0

Positionen und Funktionen

• Seit 04/1994 Medizinische Universität Wien und Universitätsklinikum AKH Wien/Universitätsklinik für Transfusionsmedizin und Zelltherapie
• Seit 2019 Herstellungsleitung ATMPs
• Seit 2015 Etablierung des CAR-T Zellprogramms an der Universitätsklinik für Transfusionsmedizin und Zelltherapie in Zusammenarbeit mit der Klin. Abteilung für Hämatologie und Knochenmarktransplantation der Univ. Klinik für Innere Medizin I
• Seit 2005 Medizinische Leitung der Zell- & Gewebeentnahmeeinrichtung und Gewebebank
• Seit 2005 Bereichsleitung therapeutische Apheresen

Ausbildung

• 12/2002 Fachärztin für Allgemeinmedizin
• 03/1999 Notärzt:innendiplom
• 04/1994–04/1998 Fachärzt:innenausbildung Blutgruppenserologie und Transfusionsmedizin, Medizinische Universität Wien
• 10/1983–10/1989 Studium der Humanmedizin, Medizinische Universität Wien

Experimentelle und klinische Forschung

• 2016–2022 Klinische Studienaktivitäten als Principal Investigator und Subinvestigator im Bereich Zelltherapie
• 09/2018–11/2018 Fellowship an der Medizinischen Hochschule Hannover und Fraunhofer Institut für Zelltherapie und Immunologie Leipzig
• 10/2003 Habilitation und Lehrbefugnis für das Fach Blutgruppenserologie und Transfusionsmedizin an der Medizinischen Universität Wien: „Immunhämatologische Probleme nach allogener Knochenmarktransplantation“

Ehrungen, Auszeichnungen, Förderung

• 2019 Erwin Domanig Award of the Austrian Society for Blood Group Serology and Transfusion Medicine
• 2013 Best Oral Abstract Award of the German Society for Transfusion Medicine and Immunehematology
• 2011 Erwin Domanig Award of the Austrian Society for Blood Group Serology and Transfusion Medicine
• 2003 Award of the Austrian Society for Transplantation, Transfusion and Genetic, Austrotransplant

Peer-Review-Förderungen (§ 26)

1. Principal Investigator

• 2021 Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung
• 2010 Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien (BGM)

2. Subinvestigator

• 2010 EU Projekt: FP7-HEALTH-2010-single-stage “academic GMP”
• 2018 Trex A prospective controlled trial of in vitro expanded recipient regulatory T cell therapy and tocilizumab together with donor bone marrow infusion in HLA-mismatched living donor kidney transplant recipients (WWTF)

Industrie-Förderungen (§ 27)

1. Principal Investigator

• APN401-103 Phase 1b Open-Label, Multi-Center, Dose Escalation and Expansion Study of APN401 in Patients with Advanced Solid Tumors
• ATA129-EBV-205 An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
• ATA129-EBV-302 Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
• CCTL019B2206 A multicentre study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
• OPTIMIZE Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results

2. Subinvestigator

• M-2020-371 - Daly 2 A pivotal Phase II randomised, multicentre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with R-R DLBCL, who are not eligible for HD-CHT and Autologous Stem Cell Transplantation (“Clinical Study”)
• JCAR017-FOL-001 A phase 2, Open Label, Single-Arm, multicohort, Multi-Center Trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)
• CYTB323A12101 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL
• CTL19 H2301 Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
• CTL019J2101 Phase Ib study of tisagenlecleucel in combination with pembrolizumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients (PORTIA)
• JCAR017-BCM-001 A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma
• CCTL019A2205B Long Term Follow-Up of patients exposed to Lentiviral-based CD19 directed CART cell therapy
• CCTL019C2201 A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)